Financial Data and Key Metrics Changes - Total company revenues for Q4 2025 were $16.4 billion, reflecting a 5% increase, or 4% excluding foreign exchange impact [12] - Earnings per share (EPS) were reported at $2.04, with guidance for 2026 EPS expected to be between $5.00 and $5.15 [19][20] Business Line Data and Key Metrics Changes - Oncology sales, including Keytruda, increased by 5% to $8.4 billion, driven by strong demand in earlier-stage cancers and metastatic indications [13] - Sales of Welireg increased by 37% to $220 million, primarily due to increased use in advanced renal cell carcinoma [15] - Gardasil sales decreased by 35% to $1 billion, attributed to lower demand in China and Japan [15] - The animal health business grew by 6%, with livestock sales increasing by 9% [18] Market Data and Key Metrics Changes - In the U.S., Keytruda's growth was negatively impacted by approximately $200 million due to the timing of purchases [14] - Sales of Capvaxive reached $279 million, driven by demand from retail pharmacies and increased seasonal immunization activity [15] - Winrevair achieved global sales of $467 million, reflecting strong demand for pulmonary arterial hypertension treatment [16] Company Strategy and Development Direction - The company aims to deliver transformative medicines and vaccines, with a focus on breakthrough science and innovation [4] - A significant commercial opportunity of over $70 billion is projected by the mid-2030s, bolstered by new product launches and acquisitions [5] - The company is committed to investing in its innovative pipeline and key growth drivers, with a focus on sustainable long-term value [12][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver sustainable growth post-Keytruda LOE, with a robust pipeline and strategic business development [5][21] - The company anticipates growth in 2026 driven by new product launches and continued strength in oncology and animal health, despite challenges from generic competition [21][22] Other Important Information - The company completed the acquisition of Cidara Therapeutics, enhancing its portfolio in infectious diseases [8][26] - The company expects to see significant growth in its animal health business, with projections to double by the mid-2030s [21] Q&A Session Summary Question: Can you elaborate on the CD388 asset and its potential? - Management highlighted the importance of robust data across multiple geographies and seasons for the ongoing trial, emphasizing the need for strong data to support future labeling [38][39] Question: Are there plans to explore sac-TMT in first-line settings? - Management indicated that they view sac-TMT as a potential best-in-class asset and have a robust program with multiple phase 3 studies planned [43][44] Question: How should the intellectual property runway for Keytruda be modeled? - Management clarified that while the compound patent expires in December 2028, there are additional patents extending to 2029, and they remain confident in defending these patents [48][49] Question: What is the significance of the dual regimen for HIV treatment? - Management emphasized the potential of Islatravir as a next-generation nucleoside analog, providing new options for patients and addressing unmet needs in HIV treatment [53][54] Question: What is the outlook for Merck's growth in the coming years? - Management expressed confidence in sustainable growth driven by a strong pipeline and significant commercial opportunities, despite challenges from LOEs [60][61]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Fourth-Quarter 2025 Sales and Earnings Merck & Co., Inc., Rahway, N.J., USA February 3, 2026 Strategy and Business Update Robert M. Davis Chairman and Chief Executive Officer Financial Results and Outlook Caroline Litchfield Executive Vice President and Chief Financial Officer Research Update Dr. Dean Y. Li Executive Vice President and President, Research Laboratories Question & Answer Session 2 Agenda Agenda Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This presentation of Merck & Co., ...

Core Insights - Merck reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and showing an increase from $1.72 per share a year ago, resulting in an earnings surprise of +0.62% [1] - The company achieved revenues of $16.4 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.33% and up from $15.62 billion year-over-year [2] - Merck's stock has increased by approximately 7.7% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] Earnings Outlook - The future performance of Merck's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $16.13 billion, and for the current fiscal year, it is $6.20 on revenues of $67.36 billion [7] Estimate Revisions - Prior to the earnings release, the estimate revisions trend for Merck was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] Industry Context - The Large Cap Pharmaceuticals industry, to which Merck belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Eli Lilly, is expected to report quarterly earnings of $6.99 per share, reflecting a year-over-year increase of +31.4%, with revenues projected at $17.87 billion, up 32.1% from the previous year [9][10]

Group 1 - PepsiCo's snack division, Frito-Lay, is struggling due to the impact of GLP-1 weight loss drugs, prompting concerns about the company's future performance [1] - CEO Ramon Laguarta may take significant actions to reduce the company's reliance on snacks, indicating potential strategic shifts [1] - Despite these challenges, PepsiCo's stock closed nearly five points higher, suggesting market optimism or a broader positive trend following a strong quarter from Colgate [1] Group 2 - The market is currently seeing declines in traditional safety stocks, with PepsiCo down over 8% for the year, although it has a 4% yield and is under pressure from an activist firm [3] - Comparatively, other companies like Conagra have experienced even steeper declines, with a nearly 33% drop, highlighting the challenging environment for food and beverage stocks [3]

Merck closed the fourth quarter with earnings and revenue ahead of Wall Street estimates, supported by strong demand for its blockbuster cancer drug Keytruda and accelerating sales from newer medicine... ...

Core Viewpoint - Merck's stock has declined due to full-year revenue and profit forecasts falling short of market expectations [1] Group 1: Financial Performance - The company's full-year revenue outlook is below expectations, indicating potential challenges in meeting market demands [1] - Profit forecasts for the year also did not meet analyst predictions, contributing to the stock decline [1] Group 2: Market Reaction - Following the announcement of the disappointing outlook, Merck's stock experienced a notable drop, reflecting investor concerns [1]

While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initiated its adjusted earnings and net sales guidance for the full-year 2026.For fiscal 2026, Merck now projects adjusted earnings in a range of $5.00 to $5.15 per share on sales between $65.5 billion and $67.0 billion.On average, analysts polled expect the company to report earnings of $5.63 per share on sales of $67.58 billion for the year. Ana ...

Core Viewpoint - Merck anticipates a decline in earnings for 2026 due to the acquisition of Cidara Therapeutics [1] Group 1 - The acquisition of Cidara Therapeutics is expected to impact Merck's financial performance negatively in 2026 [1]

Sales Performance - Total sales for 2025 reached $65,011 million, a 5% increase compared to $64,168 million in 2024[2] - Total sales for Q4 2025 reached $16,400 million, a 5% increase from $15,624 million in Q4 2024[11] - Global pharmaceutical sales increased to $65,011 million in 2025 from $58,142 million in 2024, representing a growth of 12%[20] - Pharmaceutical sales for 2025 reached $58,142 million, a 1% increase from $57,400 million in 2024[27] - U.S. pharmaceutical sales were $36,510 million in 2025, up from $34,409 million in 2024, an increase of 6%[20] - International pharmaceutical sales decreased to $28,501 million in 2025 from $31,891 million in 2024, a decline of 11%[20] Income and Expenses - Net income attributable to Merck for 2025 was $17,117 million, down 21% from $18,254 million in 2024[2] - Earnings per share assuming dilution for 2025 was $6.74, a decrease of 20% compared to $7.28 in 2024[2] - Income before taxes for 2025 was $19,936 million, a 6% increase from $19,936 million in 2024[2] - Research and development expenses decreased by 12% to $17,938 million in 2025 from $15,789 million in 2024[2] - Selling, general and administrative expenses for 2025 were $10,733 million, a slight decrease of 1% from $10,816 million in 2024[2] - Restructuring costs for 2025 totaled $889 million, with a significant increase from $309 million in 2024[2] Tax and Interest - The tax rate for 2025 was 14.1%, compared to 13.3% in 2024[2] - Interest income for 2025 was reported at $(343) million, an improvement from $(415) million in 2024[30] - Total interest expense for 2025 was $1,357 million, compared to $1,271 million in 2024[30] - Exchange losses increased to $323 million in 2025 from $227 million in 2024[30] - The total net periodic defined benefit plan cost for 2025 was $(615) million, slightly improved from $(633) million in 2024[30] Product Sales Breakdown - Pharmaceutical sales were $14,843 million in Q4 2025, up 6% from $14,042 million in Q4 2024[11] - Keytruda sales increased by 6% to $8,337 million in Q4 2025, compared to $7,836 million in Q4 2024[11] - Alliance revenue from Lynparza grew by 7% to $389 million in Q4 2025, up from $365 million in Q4 2024[11] - Total vaccines sales decreased to $2,364 million in Q4 2025, down 12% from $2,693 million in Q4 2024[15] - Total diabetes sales increased to $579 million in Q4 2025, a 6% rise from $546 million in Q4 2024[17] - Animal health sales increased by 8% to $1,505 million in Q4 2025, up from $1,397 million in Q4 2024[11] - The company reported a 37% increase in Welireg sales, reaching $220 million in Q4 2025, compared to $160 million in Q4 2024[11] - Dificid sales dropped by 68% to $25 million in Q4 2025, down from $79 million in Q4 2024[11] - Keytruda sales rose to $31,641 million in 2025, up from $29,482 million in 2024, marking an increase of 7%[20] - Total vaccines sales decreased to $10,711 million in 2025 from $13,448 million in 2024, reflecting a decline of 20%[23] - Total diabetes sales increased to $2,862 million in 2025, compared to $2,599 million in 2024, showing a growth of 10%[24] - Alliance revenue for Koselugo reached $436 million in 2025, up from $170 million in 2024, indicating a significant increase of 156%[24] - Other revenues from third-party manufacturing and miscellaneous corporate activities were $138 million in 2025, compared to $106 million in 2024, representing a growth of 30%[25] - Sales of Gardasil/Gardasil 9 dropped significantly to $5,233 million in 2025 from $8,583 million in 2024, a decrease of 39%[20] - Winrevair sales surged to $1,443 million in 2025 from $419 million in 2024, reflecting a substantial increase of over 200%[20] - Sales in Japan decreased by 18% year-over-year, with 2025 sales at $2,632 million compared to $3,199 million in 2024[27] - Sales in China dropped significantly by 66%, totaling $1,816 million in 2025 compared to $5,394 million in 2024[27] - Gardasil/Gardasil 9 sales in China were $193 million in 2025, a significant decline from $1,253 million in 2024[28]